Hydrocodone/paracetamol controlled-release - Mallinckrodt

Drug Profile

Hydrocodone/paracetamol controlled-release - Mallinckrodt

Alternative Names: Acetaminophen/hydrocodone controlled release - Mallinckrodt; COV-155; Hydrocodone bitartrate/acetaminophen extended release - Mallinckrodt; Hydrocodone/acetaminophen controlled release - Mallinckrodt; Hydrocodone/paracetamol controlled release - Mallinckrodt; Hydrocodone/paracetamol CR - Mallinckrodt; MNK-155; Paracetamol/hydrocodone - Mallinckrodt

Latest Information Update: 16 May 2016

Price : $50

At a glance

  • Originator Mallinckrodt Inc.
  • Class Acetanilides; Morphine derivatives; Non-opioid analgesics; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Acute pain
  • No development reported Back pain; Musculoskeletal pain

Most Recent Events

  • 23 Mar 2016 Mallinckrodt terminates a phase III trial for Post operative pain in USA (NCT02381132)
  • 01 Jan 2016 Phase-I clinical trials in Acute pain (In adolescents) in USA (PO) (NCT02767349)
  • 11 Jun 2015 No recent reports of development identified - Phase-III for Musculoskeletal pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top